Anti-Human EGFR (Nimotuzumab Biosimilar)
英诺赛图(InnoCyto)的 Anti-Human EGFR (Nimotuzumab Biosimilar)(克隆 Nimotuzumab) 为人源 IgG4 抗体,靶向 EGFR(别名 Proto-oncogene c-ErbB-1 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥3,051 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 Anti-Human EGFR (Nimotuzumab Biosimilar)(克隆 Nimotuzumab) 为人源 IgG4 抗体,靶向 EGFR(别名 Proto-oncogene c-ErbB-1 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥3,051 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
504101 | 1 mg | ¥3,051
504102 | 5 mg | ¥8,136
504103 | 20 mg | ¥26,442
Product Details
Product Description|Anti-Human EGFR (Nimotuzumab Biosimilar)
Regulatory Status|RUO
Species specificity|Human
Storage Conditions|4ºC
Maximal Shelf Life|12 months
See All Formats|Clone Nimotuzumab
Background Information
Nimotuzumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) subclass, engineered to selectively target the extracellular domain of the epidermal growth factor receptor (EGFR), also known as ErbB1 or HER1. Structurally, Nimotuzumab is composed of two identical heavy chains and two identical light chains interconnected by disulfide bonds, forming the characteristic Y-shaped quaternary structure of immunoglobulins. The molecule has an approximate molecular weight of 150 kilodaltons (kDa) and a glycoprotein composition typical of monoclonal antibodies expressed in mammalian systems, such as Chinese Hamster Ovary (CHO) cells, which ensure accurate folding and N-linked glycosylation.
The variable domains of the heavy (VH) and light (VL) chains contain complementarity-determining regions (CDRs) responsible for antigen recognition. Derived from murine antibody sequences and grafted onto human immunoglobulin frameworks, these CDRs define Nimotuzumab’s high-affinity, selective binding to subdomain III of the EGFR’s extracellular region. This domain is essential for the receptor’s interaction with natural ligands, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α). By binding to this epitope, Nimotuzumab competitively inhibits ligand-induced receptor dimerization and autophosphorylation, thereby blocking downstream activation of EGFR-dependent intracellular signaling cascades, including the RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways that regulate cell survival, proliferation, and differentiation.
The Fc (fragment crystallizable) region of Nimotuzumab, typical of the IgG1 isotype, provides structural stability and prolongs serum half-life through interaction with the neonatal Fc receptor (FcRn). It also allows for secondary effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement fixation under experimental conditions. Overall, Nimotuzumab exemplifies rational antibody engineering - integrating the ligand-blocking capabilities of an EGFR antagonist with the pharmacokinetic and effector properties of a stable IgG1 framework.
Data Sheets
Cat # Size Price Quantity 5041011 mg Add to Cart5041025 mg Add to Cart50410320 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). Anti-Human EGFR (Nimotuzumab Biosimilar)(504101)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-egfr-nimotuzumab-biosimilar.html.
TeleVM. (2026, November 12). Anti-Human EGFR (Nimotuzumab Biosimilar)(504101). 产品目录. https://www.suprotek.cn/products/item/anti-human-egfr-nimotuzumab-biosimilar.html
@misc{biocsp_item_anti_human_egfr_nimotuzumab_biosimilar,
title = {Anti-Human EGFR (Nimotuzumab Biosimilar)(504101)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/anti-human-egfr-nimotuzumab-biosimilar.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源